What's Happening?
The PreciseOnco research consortium, coordinated by Royal Philips, has been awarded EUR 14.9 million from the EU's Innovative Health Initiative to advance precision cancer treatment. The consortium aims to integrate advanced medical imaging, robotic guidance technologies, and AI to enhance minimally invasive cancer therapies. The five-year program, with a total budget of EUR 23.9 million, includes five clinical studies to validate these technologies. The initiative seeks to improve precision, safety, and efficiency in cancer care, addressing the rising global cancer burden projected to reach over 35 million new cases by 2050.
Why It's Important?
This initiative is significant as it addresses the growing need for precision in cancer treatment, which is crucial given
the increasing global cancer incidence. By enhancing the precision of minimally invasive treatments, the consortium aims to improve patient outcomes and optimize hospital resources. The integration of AI and advanced imaging technologies could set new benchmarks in cancer care, potentially reducing recovery times and side effects compared to traditional surgery. This project exemplifies the potential of public-private partnerships in driving healthcare innovation.
What's Next?
The PreciseOnco consortium will conduct five clinical studies across various cancer types to validate the new technologies in real-world settings. These studies will generate evidence to support the adoption of spectral imaging and robotic guidance in European cancer centers, potentially expanding access to advanced treatments. The project will also focus on developing imaging biomarkers to predict treatment success, which could further personalize cancer care. The outcomes of these studies could influence future healthcare policies and practices in cancer treatment.
